bymuratdeniz/E+ via Getty Images Topline phase 2b data on Oculis Holding's ( NASDAQ: OCS ) licaminlimab for dry eye disease found that the biologic showed a positive treatment effect in several sign endpoints such as fluorescein staining in the total cornea, inferior corneal, central corneal and nasal conjunctival regions. In a subpopuation of patients with the TNFR1 genetic biomarker, improvement in corneal inflammation was observed as early as day 15 and grew to significance by day 43. Ocular treatment-emergent adverse events were 11.
5% in the licaminlimab group and 10.2% in the vehicle cohort. Oculis (OCS) is looking to have an end-of-phase 2 meeting with the U.
S. FDA to discuss the registration path for licaminlimab as well as finalize the phase 3 development plan. More on Oculis Holding Seeking Alpha’s Quant Rating on Oculis Holding Historical earnings data for Oculis Holding Financial information for Oculis Holding.
